Starting Dose of Veltassa (Patiromer)
The recommended starting dose of Veltassa is 8.4 grams once daily for adults, and 4 grams once daily for pediatric patients ages 12 years and older 1.
Dosing Algorithm by Age
Adults
- Initial dose: 8.4 grams patiromer orally once daily
- Titration: Increase in increments of 8.4 grams based on serum potassium levels
- Timing: At 1-week or longer intervals
- Maximum dose: 25.2 grams once daily 1
Pediatric Patients (≥12 years)
- Initial dose: 4 grams patiromer orally once daily
- Titration: Increase in increments of 4 grams based on serum potassium levels
- Timing: At 1-week or longer intervals
- Maximum dose: 25.2 grams once daily 1
Clinical Context from Trials
The FDA-approved starting dose of 8.4 grams for adults is supported by extensive clinical trial data. In the OPAL-HK phase 3 trial, patients with moderate to severe hyperkalemia (K+ 5.5-6.5 mEq/L) received 8.4 grams twice daily (16.8 grams total daily), while those with mild hyperkalemia (K+ 5.1-5.5 mEq/L) received 4.2 grams twice daily (8.4 grams total daily) 2. The AMETHYST-DN trial similarly demonstrated efficacy with starting doses ranging from 4.2 to 16.8 grams twice daily depending on hyperkalemia severity 2.
However, the FDA label clearly specifies once-daily dosing as the approved regimen, not the twice-daily dosing used in many clinical trials 1. This represents an important distinction between research protocols and real-world prescribing.
Important Administration Requirements
- Timing with other medications: Administer at least 3 hours before or after other oral medications (except those without clinically important interactions) 1
- Preparation: Mix with water or soft foods; never take in dry form or heat the medication 1
- Onset of action: Approximately 7 hours, making it unsuitable for emergency hyperkalemia treatment 2
Monitoring and Titration Strategy
Monitor serum potassium levels and adjust the dose to achieve target potassium range (typically 3.8-5.0 mEq/L). Real-world data from hemodialysis patients showed that the 8.4 gram once-daily dose was most commonly prescribed (91.2% of patients), with infrequent need for dose titration 3. In clinical trials, mean serum potassium reductions of 0.35-0.97 mEq/L were achieved within 4 weeks depending on baseline severity and starting dose 2, 4.
Common Pitfall
Do not confuse the twice-daily dosing used in clinical trials with the FDA-approved once-daily regimen. The approved starting dose is 8.4 grams once daily for adults, not 8.4 grams twice daily.